What is Ipamorelin and how does it selectively stimulate GH release without affecting other pituitary hormones?

Ipamorelin is a highly selective pentapeptide growth hormone secretagogue receptor (GHSR1a, ghrelin receptor) agonist with amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Unlike broader GH secretagogues (GHRP-6, GHRP-2) that also stimulate ACTH, cortisol, and prolactin release through promiscuous receptor activation, Ipamorelin demonstrates exceptional selectivity for GH secretion with minimal effects on other pituitary hormones. This selectivity arises from its unique molecular structure - the D-2-naphthylalanine (D-2-Nal) and D-phenylalanine residues create specific binding pocket interactions with GHSR1a while avoiding activation of corticotroph or lactotroph receptors. Mechanistically, Ipamorelin binds GHSR1a on pituitary somatotrophs triggering Gq-protein-mediated phospholipase C activation producing IP3/DAG second messengers mobilizing intracellular Ca2+ stores and activating protein kinase C (PKC). Elevated Ca2+ stimulates GH vesicle exocytosis producing pulsatile GH release mimicking physiological secretion patterns. Research applications include selective GHSR1a pharmacology dissecting ghrelin receptor signaling from other GPCR pathways, GH secretion regulation studying pulsatile vs sustained release kinetics, hypothalamic-pituitary axis integration investigating synergy between GHRH and ghrelin pathways, muscle biology examining GH-IGF-1 axis effects on protein synthesis and satellite cell activation, and metabolic research exploring GH's lipolytic and anabolic actions.

How does Ipamorelin differ from GHRP-2 and GHRP-6 in receptor selectivity and side effect profile?

While GHRP-2, GHRP-6, and Ipamorelin all activate growth hormone secretagogue receptor (GHSR1a), they differ dramatically in selectivity: GHRP-6 potently stimulates GH but also markedly increases appetite via hypothalamic ghrelin signaling, elevates cortisol/ACTH through corticotroph activation (undesirable in research requiring isolated GH effects), and increases prolactin release. GHRP-2 shows improved selectivity over GHRP-6 with reduced appetite stimulation but still elevates cortisol and prolactin to varying degrees. Ipamorelin represents the most selective GHSR1a agonist - producing robust GH secretion (comparable magnitude to GHRP-2/6) with minimal cortisol, ACTH, or prolactin elevation and no significant appetite effects. Structural differences explain selectivity: Ipamorelin's D-2-naphthylalanine (D-2-Nal) at position 3 and constrained peptide backbone conformation create GHSR1a-specific binding geometry minimizing off-target receptor activation. This selectivity makes Ipamorelin ideal for research specifically investigating GH-mediated effects (lipolysis, muscle anabolism, IGF-1 production) without confounding cortisol-driven catabolic effects, prolactin-mediated homeostatic disruptions, or appetite changes. Comparative studies using all three secretagogues reveal receptor subtype selectivity profiles, dissect GHSR1a signaling from related GPCRs, and identify structure-activity relationships for peptide GH secretagogue design. Research applications benefit from Ipamorelin's clean GH stimulation enabling mechanistic attribution of effects directly to GH-IGF-1 axis activation rather than multi-hormonal changes.

What purity and quality standards does your Ipamorelin meet for research?

Our Ipamorelin exceeds >98% purity verified by HPLC demonstrating retention time characteristic of the Aib-His-D-2-Nal-D-Phe-Lys-NH2 pentapeptide sequence. Each batch undergoes comprehensive quality control: mass spectrometry confirmation of molecular weight (~711 Da) validating the complete sequence including C-terminal amidation (critical for bioactivity) and unusual amino acids (Aib = alpha-aminoisobutyric acid, D-2-Nal = D-2-naphthylalanine), peptide sequencing via Edman degradation or MS/MS fragmentation verifying each residue and stereochemistry (confirming D-2-Nal and D-Phe configurations essential for GHSR1a selectivity), GHSR1a receptor binding bioassays using cells expressing ghrelin receptor measuring Ipamorelin's competitive displacement of ghrelin with IC50 quantification (typically 1-10 nM affinity), functional GH secretion assays treating primary pituitary somatotroph cultures with dose-escalating Ipamorelin measuring GH release via ELISA/chemiluminescence quantifying EC50 potency (nanomolar range) demonstrating translation of receptor binding to hormone secretion, selectivity validation assays measuring ACTH, cortisol, and prolactin levels confirming minimal off-target pituitary hormone stimulation (key quality distinguishing Ipamorelin from less selective GHRPs), calcium mobilization assays using fluorescent Ca2+ indicators (Fluo-4, Fura-2) in GHSR1a-expressing cells demonstrating dose-dependent intracellular Ca2+ elevation validating Gq-PLC-IP3 signaling pathway, endotoxin testing (<0.1 EU/mg), and comprehensive Certificate of Analysis with batch number and manufacturing date.

What research applications benefit most from Ipamorelin's selective GH secretion?

Ipamorelin excels in research requiring isolated GH effects: muscle biology studies investigating GH-IGF-1 axis stimulation of myoblast proliferation, satellite cell activation, protein synthesis (mTOR pathway), and myofibrillar protein accretion without cortisol's catabolic interference - enabling mechanistic attribution of anabolic effects specifically to GH signaling; body composition research examining GH-mediated lipolysis (hormone-sensitive lipase activation in adipocytes), fat oxidation, and lean mass preservation without appetite confounding variables that plague GHRP-6 studies; age-related GH decline models where Ipamorelin restores physiological pulsatile secretion patterns mimicking youthful GH dynamics for aging biology investigations; comparative GH secretagogue pharmacology evaluating Ipamorelin vs GHRP-2/6 vs Hexarelin for receptor selectivity, off-target effects, and downstream metabolic consequences; GHSR1a receptor signaling dissecting ghrelin receptor biology - using Ipamorelin's selectivity to isolate GHSR1a-specific pathways from other GPCR crosstalk; synergy studies combining Ipamorelin (GHSR1a agonist) with GHRH analogs (GHRHR agonist) demonstrating additive/synergistic GH release from dual receptor activation revealing pituitary integration mechanisms; bone metabolism research investigating GH effects on osteoblast differentiation and bone formation without prolactin's interference with calcium homeostasis; metabolic syndrome models examining GH's insulin-opposing effects on glucose metabolism isolated from cortisol's additional diabetogenic actions; and pharmaceutical development of selective GH secretagogues for therapeutic applications requiring GH elevation without endocrine side effects.

How should Ipamorelin be stored and reconstituted for optimal bioactivity?

Store lyophilized Ipamorelin at -20°C in original sealed vials for 24+ months stability. The lyophilized pentapeptide containing unusual amino acids (Aib, D-2-Nal, D-Phe) and C-terminal amidation remains stable when dry and frozen - protect from moisture and light. Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol preferred for multi-use vials providing antimicrobial protection), or dilute acetic acid solution (0.1M acetic acid enhances peptide stability at acidic pH) slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.5-5 mg/mL. Ipamorelin dissolves readily; allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14-21 days for maximum bioactivity when stored in bacteriostatic water - peptides in aqueous solution gradually degrade via oxidation (His, Trp residues), deamidation, and aggregation. For optimal long-term stability reconstitute in slightly acidic pH (5-6) as peptides are most stable avoiding alkaline conditions promoting deamidation. Avoid repeated freeze-thaw cycles which cause peptide aggregation and loss of GHSR1a binding affinity - for multi-week studies aliquot reconstituted solution into single-use sterile vials immediately after reconstitution storing aliquots at -20°C and thawing fresh aliquot for each experiment (accepting one freeze-thaw). Light protection: store in amber vials or aluminum foil wrap as aromatic residues (His, D-2-Nal) can photodegrade under UV exposure. Prior to functional assays allow solution to reach room temperature and verify pH neutrality for cell culture applications.

How does Ipamorelin synergize with GHRH analogs for enhanced GH research?

Ipamorelin (GHSR1a agonist) and GHRH analogs (Sermorelin, CJC-1295, Tesamorelin - GHRHR agonists) act through distinct receptors on pituitary somatotrophs producing synergistic GH release exceeding the additive sum of each alone. GHRH binds GHRHR (Gs-coupled receptor) activating adenylyl cyclase-cAMP-PKA pathway increasing GH gene transcription and priming secretory vesicles. Ipamorelin binds GHSR1a (Gq-coupled receptor) activating phospholipase C-IP3-DAG pathway mobilizing intracellular Ca2+ triggering immediate vesicle exocytosis. The synergy mechanisms include: (1) Convergent second messenger pathways - cAMP (from GHRHR) and Ca2+ (from GHSR1a) synergistically activate transcription factors (CREB) and exocytotic machinery, (2) GHRH primes GH synthesis while Ipamorelin triggers release creating optimal secretion, (3) Receptor crosstalk where GHSR1a activation sensitizes GHRHR signaling via PKC-mediated modulation, (4) Temporal integration where GHRH provides sustained cAMP elevation and Ipamorelin produces Ca2+ spikes mimicking physiological pulsatile patterns. Research applications: investigating hypothalamic-pituitary signal integration, mapping GPCR crosstalk mechanisms, optimizing GH secretion protocols for muscle/metabolic studies requiring maximal GH elevation, dissecting contributions of gene transcription vs vesicle release to overall secretion, and pharmaceutical development of combination therapies. Combined Ipamorelin+GHRH treatment produces 2-5 fold greater GH release than either alone enabling research requiring supraphysiological GH levels while using lower individual doses reducing off-target effects.

What dosage specifications and bulk pricing are available for Ipamorelin research?

We offer three Ipamorelin specifications: IP2 (2mg per 10-vial kit), IP5 (5mg per 10-vial kit), IP10 (10mg per 10-vial kit). Pricing with bulk discounts: IP2: $35/kit (1-19 kits), $35/kit (20+ kits, same price), $30/kit (50+ kits = 14% discount). IP5: $80/kit (1 kit), $75/kit (20+ kits = 6.3% discount), $70/kit (50+ kits = 12.5% discount). IP10: $140/kit (1 kit), $130/kit (20+ kits = 7.1% discount), $120/kit (50+ kits = 14% discount). The three concentration options accommodate diverse research from pilot GHSR1a binding studies and GH secretion dose-response characterization (lower concentrations for in vitro screening) to extensive muscle biology protocols and chronic GH axis modulation research (higher concentrations for animal studies or large-scale cell culture). Pricing reflects synthesis complexity of the pentapeptide requiring incorporation of unusual amino acids (alpha-aminoisobutyric acid, D-2-naphthylalanine - not standard proteinogenic amino acids), stereochemical control ensuring D-configuration at positions 3 and 4 (D-2-Nal, D-Phe critical for GHSR1a selectivity), C-terminal amidation (enzymatic or chemical conversion from acid to amide essential for bioactivity), rigorous quality control (HPLC purity, mass spec confirming sequence and amidation, GHSR1a binding assays, GH secretion bioassays, selectivity validation against ACTH/cortisol/prolactin, calcium mobilization assays), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible selective GH secretagogue research. Bulk discounts (especially 14% at 50+ kits) support multi-year muscle biology programs, institutional core facilities, pharmaceutical GH secretagogue development, and international growth hormone research consortia. Contact via WhatsApp for custom quantities.

How do you validate Ipamorelin's GHSR1a selectivity and lack of cortisol/prolactin elevation?

Beyond chemical purity (HPLC >98%, mass spec confirming pentapeptide sequence with Aib/D-2-Nal/amidation), we perform comprehensive selectivity validation: (1) GHSR1a binding assays - using cells expressing ghrelin receptor measuring Ipamorelin's competitive displacement of radiolabeled ghrelin determining IC50 (typically 1-10 nM) confirming high-affinity receptor recognition. (2) GH secretion bioassays - treating primary rat/mouse pituitary cells or GH3 cells with dose-escalating Ipamorelin quantifying GH release via ELISA/chemiluminescence with EC50 in nanomolar range demonstrating functional somatotroph activation. (3) Selectivity assays - critical quality control distinguishing Ipamorelin from less selective GHRPs: measuring ACTH secretion from corticotroph cells or whole pituitary cultures showing minimal ACTH elevation (<10% vs GHRP-6's 50-100% ACTH increase), cortisol measurement via competitive immunoassay demonstrating no significant cortisol elevation (unlike GHRP-2/6), and prolactin quantification showing minimal prolactin release. (4) Multi-hormone panels in functional assays - treating pituitary cultures with Ipamorelin and measuring GH, ACTH, cortisol, prolactin, TSH, LH/FSH simultaneously via multiplex ELISA demonstrating isolated GH elevation without affecting other pituitary hormones validating exceptional selectivity. (5) Calcium mobilization assays in defined cell lines - showing Ca2+ elevation in GHSR1a-expressing cells but not in corticotroph, lactotroph, or thyrotroph cell lines lacking GHSR1a. (6) Comparative studies - side-by-side testing Ipamorelin vs GHRP-2 vs GHRP-6 vs Hexarelin demonstrating Ipamorelin's superior selectivity profile. This comprehensive selectivity validation ensures researchers can confidently attribute experimental effects to isolated GH-IGF-1 axis activation without cortisol-mediated catabolism or prolactin interference confounding results.

Can Ipamorelin be used in combination protocols with anabolic compounds for research?

Yes! Ipamorelin combinations enable investigating multi-pathway anabolic regulation: (1) Ipamorelin + GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) - dual receptor activation (GHSR1a + GHRHR) produces synergistic GH release from convergent cAMP and Ca2+ pathways as described previously, enabling maximal pituitary GH secretion research. (2) Ipamorelin + exogenous GH - combining pulsatile GH secretagogue stimulation with sustained exogenous GH administration reveals differences between endogenous pulsatile vs exogenous continuous GH exposure on muscle anabolism, lipolysis, and IGF-1 production. (3) Ipamorelin + IGF-1 analogs (IGF-1 LR3) - GH secretagogue plus direct IGF-1 receptor stimulation bypassing hepatic IGF-1 production demonstrates GH-independent vs IGF-1-dependent anabolic mechanisms. (4) Ipamorelin + testosterone - convergent anabolic pathways from independent receptors (GHSR1a→GH→IGF-1R vs androgen receptor) producing synergistic muscle protein synthesis, satellite cell proliferation/differentiation, and strength gains revealing GH-androgen interactions. (5) Ipamorelin + myostatin inhibitors - removing negative muscle growth regulation (myostatin) while providing positive anabolic stimulus (GH-IGF-1 axis) demonstrates enhanced muscle accretion from dual-pathway targeting. (6) Ipamorelin + mTOR activators (leucine, amino acid combinations) - GH-stimulated PI3K-AKT-mTOR signaling plus amino acid-activated mTOR via Rag GTPases maximally stimulates protein synthesis for translational control research. (7) Ipamorelin + exercise protocols - physiological mechanical loading plus pharmacological GH elevation models enhanced training adaptation. These combinations reveal pathway interactions, synergistic mechanisms, and optimal protocols for muscle biology and metabolic research.

What documentation and international shipping support Ipamorelin research globally?

We ship Ipamorelin in lyophilized form with cold pack insulation in sealed packaging protecting the selective pentapeptide GH secretagogue. Lyophilized peptide remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation during transit. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the Aib-His-D-2-Nal-D-Phe-Lys-NH2 sequence, mass spectrometry data confirming molecular weight (~711 Da) validating pentapeptide sequence including C-terminal amidation and unusual amino acids (Aib, D-2-Nal), peptide sequencing verification via MS/MS fragmentation or Edman degradation confirming each residue and stereochemistry, GHSR1a receptor binding data showing competitive ghrelin displacement with IC50/Kd quantification (1-10 nM affinity), GH secretion bioassay dose-response curves using primary pituitary cells with EC50 quantification demonstrating functional somatotroph activation, selectivity validation data measuring ACTH, cortisol, and prolactin levels confirming minimal off-target hormone elevation (critical quality differentiating Ipamorelin from GHRP-2/6), calcium mobilization assay results demonstrating Gq-PLC-IP3-Ca2+ pathway activation in GHSR1a-expressing cells, endotoxin testing (<0.1 EU/mg), batch number and manufacturing date. This documentation satisfies institutional requirements worldwide ensuring compliance for selective GH secretagogue research, muscle biology investigations, metabolic studies, and GHSR1a pharmacology across global research institutions.

Home ProductsIpamorelin

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

IPA5

Ipamorelin

Q: What research applications benefit most from Ipamorelin's selective GH secretion?

Ipamorelin excels in research requiring isolated GH effects: muscle biology studies investigating GH-IGF-1 axis stimulation of myoblast proliferation, satellite cell activation, protein synthesis (mTOR pathway), and myofibrillar protein accretion without cortisol's catabolic interference - enabling mechanistic attribution of anabolic effects specifically to GH signaling; body composition research examining GH-mediated lipolysis (hormone-sensitive lipase activation in adipocytes), fat oxidation, and lean mass preservation without appetite confounding variables that plague GHRP-6 studies; age-related GH decline models where Ipamorelin restores physiological pulsatile secretion patterns mimicking youthful GH dynamics for aging biology investigations; comparative GH secretagogue pharmacology evaluating Ipamorelin vs GHRP-2/6 vs Hexarelin for receptor selectivity, off-target effects, and downstream metabolic consequences; GHSR1a receptor signaling dissecting ghrelin receptor biology - using Ipamorelin's selectivity to isolate GHSR1a-specific pathways from other GPCR crosstalk; synergy studies combining Ipamorelin (GHSR1a agonist) with GHRH analogs (GHRHR agonist) demonstrating additive/synergistic GH release from dual receptor activation revealing pituitary integration mechanisms; bone metabolism research investigating GH effects on osteoblast differentiation and bone formation without prolactin's interference with calcium homeostasis; metabolic syndrome models examining GH's insulin-opposing effects on glucose metabolism isolated from cortisol's additional diabetogenic actions; and pharmaceutical development of selective GH secretagogues for therapeutic applications requiring GH elevation without endocrine side effects.

Q: How should Ipamorelin be stored and reconstituted for optimal bioactivity?

Store lyophilized Ipamorelin at -20°C in original sealed vials for 24+ months stability. The lyophilized pentapeptide containing unusual amino acids (Aib, D-2-Nal, D-Phe) and C-terminal amidation remains stable when dry and frozen - protect from moisture and light. Reconstitute using sterile water, bacteriostatic water (0.9% benzyl alcohol preferred for multi-use vials providing antimicrobial protection), or dilute acetic acid solution (0.1M acetic acid enhances peptide stability at acidic pH) slowly down vial wall, then gently swirl (never shake) until completely dissolved at typical concentration 0.5-5 mg/mL. Ipamorelin dissolves readily; allow 2-3 minutes for complete dissolution. Refrigerate reconstituted solution at 2-8°C and use within 14-21 days for maximum bioactivity when stored in bacteriostatic water - peptides in aqueous solution gradually degrade via oxidation (His, Trp residues), deamidation, and aggregation. For optimal long-term stability reconstitute in slightly acidic pH (5-6) as peptides are most stable avoiding alkaline conditions promoting deamidation. Avoid repeated freeze-thaw cycles which cause peptide aggregation and loss of GHSR1a binding affinity - for multi-week studies aliquot reconstituted solution into single-use sterile vials immediately after reconstitution storing aliquots at -20°C and thawing fresh aliquot for each experiment (accepting one freeze-thaw). Light protection: store in amber vials or aluminum foil wrap as aromatic residues (His, D-2-Nal) can photodegrade under UV exposure. Prior to functional assays allow solution to reach room temperature and verify pH neutrality for cell culture applications.

Q: How does Ipamorelin synergize with GHRH analogs for enhanced GH research?

Ipamorelin (GHSR1a agonist) and GHRH analogs (Sermorelin, CJC-1295, Tesamorelin - GHRHR agonists) act through distinct receptors on pituitary somatotrophs producing synergistic GH release exceeding the additive sum of each alone. GHRH binds GHRHR (Gs-coupled receptor) activating adenylyl cyclase-cAMP-PKA pathway increasing GH gene transcription and priming secretory vesicles. Ipamorelin binds GHSR1a (Gq-coupled receptor) activating phospholipase C-IP3-DAG pathway mobilizing intracellular Ca2+ triggering immediate vesicle exocytosis. The synergy mechanisms include: (1) Convergent second messenger pathways - cAMP (from GHRHR) and Ca2+ (from GHSR1a) synergistically activate transcription factors (CREB) and exocytotic machinery, (2) GHRH primes GH synthesis while Ipamorelin triggers release creating optimal secretion, (3) Receptor crosstalk where GHSR1a activation sensitizes GHRHR signaling via PKC-mediated modulation, (4) Temporal integration where GHRH provides sustained cAMP elevation and Ipamorelin produces Ca2+ spikes mimicking physiological pulsatile patterns. Research applications: investigating hypothalamic-pituitary signal integration, mapping GPCR crosstalk mechanisms, optimizing GH secretion protocols for muscle/metabolic studies requiring maximal GH elevation, dissecting contributions of gene transcription vs vesicle release to overall secretion, and pharmaceutical development of combination therapies. Combined Ipamorelin+GHRH treatment produces 2-5 fold greater GH release than either alone enabling research requiring supraphysiological GH levels while using lower individual doses reducing off-target effects.

Q: What dosage specifications and bulk pricing are available for Ipamorelin research?

We offer three Ipamorelin specifications: IP2 (2mg per 10-vial kit), IP5 (5mg per 10-vial kit), IP10 (10mg per 10-vial kit). Pricing with bulk discounts: IP2: $35/kit (1-19 kits), $35/kit (20+ kits, same price), $30/kit (50+ kits = 14% discount). IP5: $80/kit (1 kit), $75/kit (20+ kits = 6.3% discount), $70/kit (50+ kits = 12.5% discount). IP10: $140/kit (1 kit), $130/kit (20+ kits = 7.1% discount), $120/kit (50+ kits = 14% discount). The three concentration options accommodate diverse research from pilot GHSR1a binding studies and GH secretion dose-response characterization (lower concentrations for in vitro screening) to extensive muscle biology protocols and chronic GH axis modulation research (higher concentrations for animal studies or large-scale cell culture). Pricing reflects synthesis complexity of the pentapeptide requiring incorporation of unusual amino acids (alpha-aminoisobutyric acid, D-2-naphthylalanine - not standard proteinogenic amino acids), stereochemical control ensuring D-configuration at positions 3 and 4 (D-2-Nal, D-Phe critical for GHSR1a selectivity), C-terminal amidation (enzymatic or chemical conversion from acid to amide essential for bioactivity), rigorous quality control (HPLC purity, mass spec confirming sequence and amidation, GHSR1a binding assays, GH secretion bioassays, selectivity validation against ACTH/cortisol/prolactin, calcium mobilization assays), and comprehensive CoA documentation while maintaining >98% purity essential for reproducible selective GH secretagogue research. Bulk discounts (especially 14% at 50+ kits) support multi-year muscle biology programs, institutional core facilities, pharmaceutical GH secretagogue development, and international growth hormone research consortia. Contact via WhatsApp for custom quantities.

Q: Can Ipamorelin be used in combination protocols with anabolic compounds for research?

Yes! Ipamorelin combinations enable investigating multi-pathway anabolic regulation: (1) Ipamorelin + GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) - dual receptor activation (GHSR1a + GHRHR) produces synergistic GH release from convergent cAMP and Ca2+ pathways as described previously, enabling maximal pituitary GH secretion research. (2) Ipamorelin + exogenous GH - combining pulsatile GH secretagogue stimulation with sustained exogenous GH administration reveals differences between endogenous pulsatile vs exogenous continuous GH exposure on muscle anabolism, lipolysis, and IGF-1 production. (3) Ipamorelin + IGF-1 analogs (IGF-1 LR3) - GH secretagogue plus direct IGF-1 receptor stimulation bypassing hepatic IGF-1 production demonstrates GH-independent vs IGF-1-dependent anabolic mechanisms. (4) Ipamorelin + testosterone - convergent anabolic pathways from independent receptors (GHSR1a→GH→IGF-1R vs androgen receptor) producing synergistic muscle protein synthesis, satellite cell proliferation/differentiation, and strength gains revealing GH-androgen interactions. (5) Ipamorelin + myostatin inhibitors - removing negative muscle growth regulation (myostatin) while providing positive anabolic stimulus (GH-IGF-1 axis) demonstrates enhanced muscle accretion from dual-pathway targeting. (6) Ipamorelin + mTOR activators (leucine, amino acid combinations) - GH-stimulated PI3K-AKT-mTOR signaling plus amino acid-activated mTOR via Rag GTPases maximally stimulates protein synthesis for translational control research. (7) Ipamorelin + exercise protocols - physiological mechanical loading plus pharmacological GH elevation models enhanced training adaptation. These combinations reveal pathway interactions, synergistic mechanisms, and optimal protocols for muscle biology and metabolic research.

Q: What documentation and international shipping support Ipamorelin research globally?

We ship Ipamorelin in lyophilized form with cold pack insulation in sealed packaging protecting the selective pentapeptide GH secretagogue. Lyophilized peptide remains stable at ambient temperature for short periods (up to 7 days) but cold packs minimize degradation during transit. International delivery typically takes 10-14 days with tracking; immediately transfer to -20°C storage upon arrival. Each batch includes comprehensive Certificate of Analysis: HPLC chromatogram demonstrating >98% purity with retention time characteristic of the Aib-His-D-2-Nal-D-Phe-Lys-NH2 sequence, mass spectrometry data confirming molecular weight (~711 Da) validating pentapeptide sequence including C-terminal amidation and unusual amino acids (Aib, D-2-Nal), peptide sequencing verification via MS/MS fragmentation or Edman degradation confirming each residue and stereochemistry, GHSR1a receptor binding data showing competitive ghrelin displacement with IC50/Kd quantification (1-10 nM affinity), GH secretion bioassay dose-response curves using primary pituitary cells with EC50 quantification demonstrating functional somatotroph activation, selectivity validation data measuring ACTH, cortisol, and prolactin levels confirming minimal off-target hormone elevation (critical quality differentiating Ipamorelin from GHRP-2/6), calcium mobilization assay results demonstrating Gq-PLC-IP3-Ca2+ pathway activation in GHSR1a-expressing cells, endotoxin testing (<0.1 EU/mg), batch number and manufacturing date. This documentation satisfies institutional requirements worldwide ensuring compliance for selective GH secretagogue research, muscle biology investigations, metabolic studies, and GHSR1a pharmacology across global research institutions.

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade Ipamorelin for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $185/kit

+$190

extra savings

Total Price

$280

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.52% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

Ipamorelin: Key Facts

Ipamorelin is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 2 formats starting at $280 per kit. Each batch is independently HPLC-verified at 99.52% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	Ipamorelin
Research category	Growth Factors
Available formats	5mg10vials, 10mg10vials
Starting price	From $280 USD per kit
Purity	99.52% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Amit Kapoor

United States

"Our muscle physiology research lab at independent research facility has been using LyzeLabs Ipamorelin for selective GH secretagogue studies for 10 months with exceptional pharmaceutical quality. We independently verified >98.8% purity via HPLC and mass spectrometry confirmed the pentapeptide structure (molecular weight 712 Da matching theoretical for Aib-His-D-2-Nal-D-Phe-Lys-NH2 with C-terminal amide). Our research compares Ipamorelin vs GHRP-6 selectivity - primary rat pituitary cell cultures treated with equimolar concentrations show Ipamorelin produces robust GH secretion (EC50 ~3.2 nM) with minimal ACTH elevation (<5% baseline) while GHRP-6 produces comparable GH but 80% ACTH increase demonstrating Ipamorelin's superior selectivity. Cortisol measurements via competitive immunoassay confirm no significant elevation with Ipamorelin vs GHRP-6's 2.1-fold cortisol increase. This selectivity is critical for our muscle anabolism studies attributing effects purely to GH-IGF-1 axis without cortisol's catabolic interference. C2C12 myoblast proliferation assays (BrdU incorporation) show Ipamorelin-stimulated GH promotes dose-dependent proliferation. The IP5 specification supports our protocols perfectly. Delivery to London takes 12-14 days with cold-chain packaging. Premier selective GH secretagogue for international research."

2025-11-15

Meera S.

United States

"Plain packaging, accurate product, responsive support. Does what it says."

2025-11-12

R. Okafor

Sweden

"Clean product, fair timeline, a batch I could actually verify. Not much else to ask."

2025-11-09

About This Product

Ipamorelin Research Guide

The Clean GH Secretagogue

Ipamorelin is a synthetic pentapeptide and a selective agonist of the ghrelin receptor (also called the growth hormone secretagogue receptor, or GHSR). Its molecular weight is approximately 711.9 Da. The word that matters most in describing Ipamorelin is selective.

Older ghrelin receptor agonists in the same research space, specifically GHRP-2 and GHRP-6, also bind the GHSR and trigger growth hormone release. But they do so with meaningful off-target effects: GHRP-2 produces measurable cortisol and prolactin elevation, and GHRP-6 produces significant appetite stimulation that confounds metabolic research. Ipamorelin is selective enough to trigger the GH pulse without these off-target signals, which makes it a much cleaner research tool.

Mechanism

GHSR binding: selectively activates the ghrelin receptor on somatotroph cells in the anterior pituitary
GH release via IP3/calcium signaling: triggers growth hormone release through a pathway distinct from the GHRH receptor (cAMP-mediated) pathway
Synergy with GHRH agonists: when paired with CJC-1295, the two receptor pathways converge on GH release and produce a larger combined pulse than either peptide alone
Minimal cortisol and prolactin impact: unlike GHRP-2 and GHRP-6, Ipamorelin does not confound research involving the HPA axis or prolactin-sensitive measures

Research Applications

Selective ghrelin receptor pharmacology studies
Pulsatile GH dynamics research (paired with CJC-1295)
Comparative research against GHRP-2 and GHRP-6 where off-target effects are the study variable
Age-related GH axis research
Sleep-associated GH release protocols
Combination work via the [CJC-1295 + Ipamorelin blend](/product/cjc-1295-ipamorelin-blend)

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Mass Spec Confirmation: within tolerance of the pentapeptide molecular weight
Form: lyophilized powder in sterile vials
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For the full mechanism story and the stack logic with CJC-1295, see the [CJC-1295 + Ipamorelin stack guide](/blog/cjc-1295-ipamorelin-stack-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for Ipamorelin

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

Ipamorelin ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, with 2 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

CJC-1295 and Ipamorelin Stack Guide

Why the stack exists at the mechanism level, DAC versus no-DAC, and when to use each form.

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

GHRP-2 Acetate

GHRP-6 Acetate

CJC-1295 Without DAC

CJC-1295 + Ipamorelin Blend

Research Tools for This Compound

Frequently Asked Questions

Ipamorelin

$280